

# Screening for Type 1 Diabetes in the Primary Care Setting

## Presented by:

Michael Haller, MD  
Professor and Chief, Pediatric Endocrinology  
University of Florida College of Medicine

## Faculty Disclosure:

Michael Haller, MD has disclosed that he is on the Scientific Advisory Board of SAbBiotherapeutics and has served as a consultant for Sanofi. He has no other relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

## CME Advisory Committee Disclosure

Conflict of interest information for the CME Advisory Committee members can be found on the following website: <https://cme.ufl.edu/disclosure/>. All relevant financial relationships have been mitigated.

**Bibliographic Source:** [haller mj - Search Results - PubMed \(nih.gov\)](#)

**Release Date:** November 30, 2023

**Expiration Date:** November 29, 2025

**Target Audience:** Pediatricians caring for children at risk for type 1 diabetes and those interested in learning about screening for T1D and how to refer patients for possible prevention and intervention studies or therapies

## Learning Objectives:

As a result of participation in this activity, participants should be able to:

1. Understand the ways to screen for T1D risk (Autoantibodies).
2. Be aware of the currently FDA approved therapies to prevent/delay T1D progression.
3. Refer potential subjects for participation in T1D research studies.

**Requirements for successful completion:** Certificates are awarded upon successful completion (80% proficiency) of the post-test.

**Accreditation:** The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit:** The University of Florida College of Medicine designates this enduring material for a maximum of .25 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Contact Info:** If you have any questions please feel free to contact Michael Haller, MD / [hallejmj@peds.ufl.edu](mailto:hallejmj@peds.ufl.edu)

[Click here to listen to lecture!](#)

[Click here to take the post test!](#)